You are not logged in |
On the optimal use of bevacizumab in unresected glioblastoma: An evidence-based mathematical approach
- Speaker(s)
- Monika J. Piotrowska i Marek Bodnar
- Affiliation
- MIM UW
- Date
- April 21, 2021, 12:15 p.m.
- Information about the event
- Zoom Meeting: https://us02web.zoom.us/j/83632151104?pwd=R25GeVZmVS9OWXprWDJBbm9FQ0h3dz09
- Seminar
- Seminar of Biomathematics and Game Theory Group
Glioblastoma (GBM) is the most common and aggressive type of brain tumor in adults, with a median patient survival slightly above one year, despite aggressive combination therapy with the alkilating agent temozolomide (TMZ) and radiation therapy. Phase III clinical trials of the combination of bevacizumab (BEV, anti-angiogenic drug) with the standard chemoradiation protocol were negative in terms of providing survival improvements. In a very interesting study, Balaña et al. (2016) sought to determine the impact of BEC on reduction of tumor size prior to chemoradiotherapy treatment in unresected GBM patients. They found that the combination of BEV and TMZ was more active than TMZ alone and may confer benefit in terms of tumor shrinkage in unresected patients. We propose a simple mathematical model of tumor growth taking into account hypoxic cells and treatments (radiotheraphy, chemotherapy and anti-angiogenic treatment). We study mathematical properties of the model. Moreover, we show that solution of the model mimic well results of clinical trials.
